PHEN’s Clinical Trials Rally’s approach of educating Black prostate cancer patients about clinical trials, as well as strategic partnerships with pharmaceutical companies to amplify this message, is contributing to greater diversity among clinical trial participants.
In addition to Pfizer’s TALAPRO-2 clinical trial featured in FDA approved post, PHEN also supported its TALAPRO-3 trial. Pfizer reported that they were able to complete this trial’s enrollment ahead of schedule which included 20% of Black patients enrolled in the U.S. Pfizer recognized PHEN’s support by stating: “This is a testament to the value that you provide and the impact you’ve had in raising awareness about the studies.”
